Tag: Nasdaq
Nasdaq: +12.5% in 15 sessions, back to 1% of the annual record
(CercleFinance.com) – The Nasdaq continues to climb, registering a 13 session of increase in a series of 15. The index tests 14,200 for the first time since August 1 (i.e.…
Wall Street: 9th rise in the Nasdaq, plunge in WTI below $75
(CercleFinance.com) – Wall Street ended without trend this Wednesday, ending in disorganized order at the end of a session devoid of ‘market movers’. But there is nevertheless reason to remain…
Biophytis receives notice of delisting from Nasdaq and announces that it will appeal this decision to the Nasdaq Hearing Committee – 10/27/2023 at 11:00 p.m.
Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down the degenerative processes linked to…
Wall Street: The Nasdaq falls back below 13,000 points
(CercleFinance.com) – After opening on a hesitant note, Wall Street plunged into the red on Wednesday, once again weakened by tensions on the bond market after the announcement of solid…
Abivax announces the completion of its IPO on the Nasdaq Global Market. – 10/24/2023 at 10:10 p.m.
ABIVAX press release Abivax announces the completion of its IPO on the Nasdaq Global Market. Abivax SA “Abivax” or the “Company”), a clinical-stage biotechnology company focused on the development of…
Abivax: setting of the introduction price on the Nasdaq Global Market
By Jean-Noël Legalland Published on 10/20/2023 at 3:06 p.m. Photo credit © Abivax (Boursier.com) — Abivax announces the…
Abivax: difficult start for the biotech on the Nasdaq – 10/20/2023 at 4:47 p.m.
(CercleFinance.com) – Abivax lost more than 14% on Friday for its first steps on the Nasdaq, reflecting both the current difficult market conditions and the recent lack of investor interest…
Abivax: difficult start for the biotech on the Nasdaq
(CercleFinance.com) – Abivax lost more than 14% on Friday for its first steps on the Nasdaq, reflecting both the current difficult market conditions and the recent lack of investor interest…
Abivax announces pricing of its IPO on the Nasdaq Global Market. – 10/20/2023 at 3:05 p.m.
ABIVAX press release Abivax announces pricing of its IPO on the Nasdaq Global Market. Abivax SA “Abivax” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutic…
Abivax: announces the IPO price of its securities on Nasdaq
(AOF) – Abivax today announces the pricing of its securities for its IPO on the Nasdaq Global Market. This introduction will be made through a capital increase of 20,325,500 new…
Abivax announces the IPO price of its securities on Nasdaq – 10/20/2023 at 3:17 p.m.
(AOF) – Abivax today announces the pricing of its securities for its IPO on the Nasdaq Global Market. This introduction will be made through a capital increase of 20,325,500 new…
Abivax: the price of the IPO on the Nasdaq at the bottom of the range – 10/20/2023 at 3:32 p.m.
(CercleFinance.com) – The French biotechnology company Abivax set a price of $11.60 on Friday for its IPO on the Nasdaq, at the bottom of the indicative range of $11.60-13 that…